Although the efficacy of Tocilizumab in COVID-19 patients with ARDS requires further evaluation in a larger randomized controlled trial, this encouraging clinical trial suggests that neutralizing mAbs against other pro-inflammatory cytokines such as IL-1 and IL-17 might also be useful (54). Here, IL1B is linked to COVID-19.